By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The peptide-based vaccine induces a t cell-dependent response
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Subscribe To Our Newsletter & Stay Updated
